颖泰生物（920819）：北交所信息更新：农药“反内卷”与海外补库助“走出泥泞”，亏损收窄迎破局

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company is expected to see a gradual recovery in its main business profitability, driven by a focus on product pricing recovery and the ongoing recovery of the pesticide industry [4] - The company reported a preliminary net profit attributable to shareholders of -250 million yuan for 2025, a year-on-year reduction in losses of 57.45% [4] - The revenue for 2025 is projected to be 5.531 billion yuan, a decrease of 2.27% year-on-year [4] - The company is adjusting its profit forecasts for 2025-2027, with expected net profits of -250 million yuan, 105 million yuan, and 201 million yuan respectively [4] Financial Summary - The total market capitalization of the company is 4.793 billion yuan, with a circulating market capitalization of 4.737 billion yuan [2] - The current stock price is 3.91 yuan, with a 1-year high of 5.09 yuan and a low of 3.31 yuan [2] - The company’s revenue is expected to grow to 6.379 billion yuan in 2026 and 7.239 billion yuan in 2027, reflecting a year-on-year growth of 15.3% and 13.5% respectively [7] - The gross profit margin is projected to improve from 10.3% in 2025 to 14.6% in 2027 [7] - The earnings per share (EPS) is expected to be -0.20 yuan in 2025, 0.09 yuan in 2026, and 0.16 yuan in 2027 [7] Industry Insights - The pesticide industry is experiencing a partial recovery, with the government’s tax policy changes aimed at addressing overcapacity and promoting high-quality development [5] - The export of pesticides is a significant growth driver, with China accounting for over 60% of the global pesticide supply [6] - The company is expected to derive over 50% of its revenue from overseas markets by 2024, benefiting from strong overseas demand [6]